Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.48 |
| ▸ | MAPT | P10636 | 5/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | PTGES | O14684 | 2/20 | 0.44 |
| ▸ | RAPGEF3 | O95398 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31254046 | 0.88 | ALDH1A1 (0.49) | ATMTDP1ALDH1A1MAPTLMNA | |
| SCHEMBL31254041 | 0.88 | ALDH1A1 (0.49) | ATMTDP1ALDH1A1MAPTLMNA | |
| SCHEMBL26086348 | 0.86 | MAPT (0.51) | ATMTDP1ALDH1A1MAPTLMNA | |
| SCHEMBL17010398 | 0.85 | MAPT (0.52) | ATMTDP1ALDH1A1MAPTLMNA | |
| SCHEMBL607025 | 0.84 | MAPT (0.67) | ATMTDP1ALDH1A1MAPTLMNA | |
| SCHEMBL34473705 | 0.82 | ATM (0.55) | ATMTDP1ALDH1A1MAPTLMNA | |
| SCHEMBL6520 | 0.82 | TDP1 (0.58) | ATMTDP1ALDH1A1MAPTLMNA | |
| SCHEMBL29445159 | 0.82 | TDP1 (0.58) | ATMTDP1ALDH1A1MAPTLMNA | |
| SCHEMBL2986961 | 0.81 | MAPT (0.48) | TDP1ALDH1A1MAPTLMNAHTT | |
| SCHEMBL12210768 | 0.81 | MAPT (0.60) | ATMTDP1ALDH1A1MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104352492-B | Extend enzyme inhibitor using arylsulfonyl derivatives as the long chain fatty acids of active ingredient | MSD K.K.公司 | 2017-12-05 | — | — | CN | disclosed |
| EP-2280001-B1 | LONG-CHAIN FATTY ACID ELONGATION ENZYME INHIBITOR COMPRISING ARYLSULFONYL DERIVATIVE AS ACTIVE INGREDIENT | MSD KK (JP) | 2014-10-15 | — | — | EP | disclosed |
| US-8557805-B2 | Fused ring compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-10-15 | — | — | US | disclosed |
| US-8420823-B2 | Long-chain fatty acyl elongase inhibitor comprising arylsulfonyl derivative as active ingredient | MSD K.K. (JP) | 2013-04-16 | — | — | US | disclosed |
| US-20120035163-A1 | NOVEL FUSED RING COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2012-02-09 | — | — | US | disclosed |
| EP-2371826-A1 | NOVEL FUSED RING COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2011-10-05 | — | — | EP | disclosed |
| EP-2280001-A1 | LONG-CHAIN FATTY ACID ELONGATION ENZYME INHIBITOR COMPRISING ARYLSULFONYL DERIVATIVE AS ACTIVE INGREDIENT | Banyu Pharmaceutical Co., Ltd. (JP) | 2011-02-02 | — | — | EP | disclosed |
| US-20110009622-A1 | LONG-CHAIN FATTY ACYL ELONGASE INHIBITOR COMPRISING ARYLSULFONYL DERIVATIVE AS ACTIVE INGREDIENT | MSD K.K. (JP) | 2011-01-13 | — | — | US | disclosed |
| US-5424280-A | Aryloxybenzene herbicidal agents | AMERICAN CYANAMID COMPANY (US) | 1995-06-13 | — | — | US | disclosed |
| EP-0647612-A1 | Aryloxybenzene herbicidal agents | AMERICAN CYANAMID COMPANY (US) | 1995-04-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009622-A1 | LONG-CHAIN FATTY ACYL ELONGASE INHIBITOR COMPRISING ARYLSULFONYL DERIVATIVE AS ACTIVE INGREDIENT | ELOVL1, ELOVL6, ELOVL3 | ATM 4212/4885TDP1 2513/4885ALDH1A1 188/4885 |
| US-20120035163-A1 | NOVEL FUSED RING COMPOUND AND USE THEREOF | GPR119, GCKR, SLC5A1 | ATM 2440/4885TDP1 3718/4885ALDH1A1 351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.